These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 24152157)
1. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Yun J; Mattsson J; Schnyder K; Fontana S; Largiadèr CR; Pichler WJ; Yerly D Clin Exp Allergy; 2013 Nov; 43(11):1246-55. PubMed ID: 24152157 [TBL] [Abstract][Full Text] [Related]
2. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. Yun J; Marcaida MJ; Eriksson KK; Jamin H; Fontana S; Pichler WJ; Yerly D J Immunol; 2014 Apr; 192(7):2984-93. PubMed ID: 24591375 [TBL] [Abstract][Full Text] [Related]
3. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Stamp LK; Day RO; Yun J Nat Rev Rheumatol; 2016 Apr; 12(4):235-42. PubMed ID: 26416594 [TBL] [Abstract][Full Text] [Related]
4. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917 [TBL] [Abstract][Full Text] [Related]
5. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Lockard O; Harmon C; Nolph K; Irvin W Ann Intern Med; 1976 Sep; 85(3):333-5. PubMed ID: 134655 [TBL] [Abstract][Full Text] [Related]
6. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MH; Williams KM; Tian YC; Juan KC; Jan Wu YJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI Ann Rheum Dis; 2015 Dec; 74(12):2157-64. PubMed ID: 25115449 [TBL] [Abstract][Full Text] [Related]
7. Detection of HLA-B*58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification. Kwok J; Kwong KM Br J Dermatol; 2013 Mar; 168(3):526-32. PubMed ID: 23066948 [TBL] [Abstract][Full Text] [Related]
8. Advances in our understanding of drug hypersensitivity. Brockow K Clin Exp Allergy; 2013 Nov; 43(11):1200-1. PubMed ID: 24152152 [No Abstract] [Full Text] [Related]
9. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. Chung WH; Pan RY; Chu MT; Chin SW; Huang YL; Wang WC; Chang JY; Hung SI J Invest Dermatol; 2015 Sep; 135(9):2237-2248. PubMed ID: 25946710 [TBL] [Abstract][Full Text] [Related]
10. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Wang CW; Dao RL; Chung WH Curr Opin Allergy Clin Immunol; 2016 Aug; 16(4):339-45. PubMed ID: 27362322 [TBL] [Abstract][Full Text] [Related]
11. The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug-reactive T cells in resolved hypersensitivity cases and drug-naïve healthy donors. Mifsud NA; Illing PT; Ho R; Tuomisto JE; Fettke H; Mullan KA; McCluskey J; Rossjohn J; Vivian J; Reantragoon R; Purcell AW Allergy; 2023 Nov; 78(11):2980-2993. PubMed ID: 37452515 [TBL] [Abstract][Full Text] [Related]
12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695 [TBL] [Abstract][Full Text] [Related]
13. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol hypersensitivity: Pathogenesis and prevention. Stamp LK; Chapman PT Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101501. PubMed ID: 32265121 [TBL] [Abstract][Full Text] [Related]
15. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116 [TBL] [Abstract][Full Text] [Related]
16. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. Panomvana D; Sripradit S; Angthararak S J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090 [TBL] [Abstract][Full Text] [Related]
17. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Ramasamy SN; Korb-Wells CS; Kannangara DR; Smith MW; Wang N; Roberts DM; Graham GG; Williams KM; Day RO Drug Saf; 2013 Oct; 36(10):953-80. PubMed ID: 23873481 [TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549 [TBL] [Abstract][Full Text] [Related]
19. Drug eruptions induced by allopurinol associated with HLA-B*5801. Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896 [TBL] [Abstract][Full Text] [Related]
20. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Yun J; Adam J; Yerly D; Pichler WJ Allergy; 2012 Nov; 67(11):1338-46. PubMed ID: 22943588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]